The Therapeutic Role of Short-Chain Fatty Acids Mediated Very Low-Calorie Ketogenic Diet-Gut Microbiota Relationships in Paediatric Inflammatory Bowel Diseases

Nutrients. 2022 Oct 3;14(19):4113. doi: 10.3390/nu14194113.


The very low-calorie ketogenic diet (VLCKD) has been recognized as a promising dietary regimen for the treatment of several diseases. Short-chain fatty acids (SCFAs) produced by anaerobic bacterial fermentation of indigestible dietary fibre in the gut have potential value for their underlying epigenetic role in the treatment of obesity and asthma-related inflammation through mediating the relationships between VLCKD and the infant gut microbiota. However, it is still unclear how VLCKD might influence gut microbiota composition in children, and how SCFAs could play a role in the treatment of inflammatory bowel disease (IBD). To overcome this knowledge gap, this review aims to investigate the role of SCFAs as key epigenetic metabolites that mediate VLCKD-gut microbiota relationships in children, and their therapeutic potential in IBD.

Keywords: children; gut microbiota; inflammatory bowel disease; short chain fatty acids; very low-calorie ketogenic diet.

Publication types

  • Review

MeSH terms

  • Child
  • Diet, Ketogenic*
  • Dietary Fiber
  • Fatty Acids, Volatile / metabolism
  • Gastrointestinal Microbiome*
  • Humans
  • Inflammatory Bowel Diseases* / metabolism


  • Dietary Fiber
  • Fatty Acids, Volatile

Grants and funding

This review received no financial support.